# FDA Grants Accelerated Approval to Atacicept (Trutakna) for IgA Nephropathy on July 7, 2026

> fda · REPORTED · 2026-07-07

On July 7, 2026, the FDA granted accelerated approval to Vera Therapeutics' atacicept-vymj (Trutakna) for adults with IgA nephropathy, making it the first dual BAFF and APRIL inhibitor cleared for this progressive kidney disease. The approval addresses a significant unmet need in a disease with limited treatment options.

About Vera Therapeutics: Vera Therapeutics is a clinical-stage immunology company developing treatments for serious immunological diseases, with atacicept targeting B cell-mediated mechanisms in kidney disease.

- Company: Vera Therapeutics
- Sector: therapeutics
- Primary source: https://lifesciencedaily.news/fda-drug-approval-decisions-july-and-august-2026/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.